ATE225660T1 - Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz - Google Patents

Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Info

Publication number
ATE225660T1
ATE225660T1 AT98912108T AT98912108T ATE225660T1 AT E225660 T1 ATE225660 T1 AT E225660T1 AT 98912108 T AT98912108 T AT 98912108T AT 98912108 T AT98912108 T AT 98912108T AT E225660 T1 ATE225660 T1 AT E225660T1
Authority
AT
Austria
Prior art keywords
cyclooxygenase
inhibitors
treat
prevent dementia
dementia
Prior art date
Application number
AT98912108T
Other languages
English (en)
Inventor
Philip Needleman
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE225660T1 publication Critical patent/ATE225660T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98912108T 1997-04-03 1998-03-30 Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz ATE225660T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4391697P 1997-04-03 1997-04-03
PCT/US1998/006143 WO1998043648A1 (en) 1997-04-03 1998-03-30 Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia

Publications (1)

Publication Number Publication Date
ATE225660T1 true ATE225660T1 (de) 2002-10-15

Family

ID=21929578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912108T ATE225660T1 (de) 1997-04-03 1998-03-30 Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Country Status (13)

Country Link
EP (1) EP0971714B1 (de)
JP (1) JP2002514208A (de)
AT (1) ATE225660T1 (de)
AU (1) AU725697B2 (de)
BR (1) BR9807920A (de)
CA (1) CA2285434A1 (de)
DE (1) DE69808607T2 (de)
DK (1) DK0971714T3 (de)
ES (1) ES2185154T3 (de)
HK (1) HK1024872A1 (de)
PT (1) PT971714E (de)
WO (1) WO1998043648A1 (de)
ZA (1) ZA982808B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727238B2 (en) 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
KR100229343B1 (ko) * 1993-11-30 1999-11-01 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5696143A (en) * 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1996038418A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
ES2247604T3 (es) * 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6342510B1 (en) * 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
EP1288206B1 (de) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren

Also Published As

Publication number Publication date
PT971714E (pt) 2002-12-31
DK0971714T3 (da) 2002-11-04
AU725697B2 (en) 2000-10-19
HK1024872A1 (en) 2000-10-27
DE69808607D1 (de) 2002-11-14
EP0971714A1 (de) 2000-01-19
WO1998043648A1 (en) 1998-10-08
AU6590498A (en) 1998-10-22
BR9807920A (pt) 2000-02-22
ES2185154T3 (es) 2003-04-16
CA2285434A1 (en) 1998-10-08
DE69808607T2 (de) 2003-06-26
ZA982808B (en) 1999-04-06
EP0971714B1 (de) 2002-10-09
JP2002514208A (ja) 2002-05-14

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE399547T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia
ATE242632T1 (de) Verwendung von betulinsäure-derivaten zur behandlung und vorbeugung von melanomen
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
ATE308880T1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
ATE128143T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3 one-derivate und verfahren zu ihrer herstellung.
ATE278399T1 (de) Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE259640T1 (de) Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
SE9602263D0 (sv) New amino acid derivatives
DE69433793D1 (de) Phosphorderivate zur behandlung von aids
ATE232191T1 (de) Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen
DE69718347D1 (de) VERWENDUNG EINER ZUSAMMENSETZUNG AUS H+, K+ -ATPase-INHIBITOREN UND GLUCOCORTIKOIDEN ZUR BEHANDLUNG VON NASENPOLYPEN
DE69937624D1 (de) Verfahren zur Behandlung von Metalloberflächen
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE59209268D1 (de) Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
DE59109225D1 (de) Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DE69228814D1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69330465D1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0971714

Country of ref document: EP

REN Ceased due to non-payment of the annual fee